Bimagrumab  (Synonyms: Anti-ACVR2B Reference Antibody; BYM338)

Bimagrumab (Anti-ACVR2B Reference Antibody) is a human monoclonal antibody that blocks activin type II receptor (ActRII), with K_Ds of 1.7 pM and 434 pM for human ActRIIB and ActRIIA, respectively. Bimagrumab can be used for the research of pathological muscle loss and weakness^[1][2].

BYM338 (1 pM-1 μM; 24 h) inhibits Myostatin- and Activin A-induced Smad2/3-dependent luciferase responses in HEK293 cells with IC₅₀s of 154 and 343 pM, respectively^[2].
BYM338 (4 days) prevents the inhibition of differentiation and fusion induced upon exogenous addition of Myostatin or Activin A^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

BYM338 (6-20 mg/kg; s.c. once weekly for 4 weeks) promotes an increase in body weight and skeletal muscle hypertrophy of all examined muscles, slow, fast, and mixed of young SCID mice^[2].
BYM338 (5-20 mg/kg; s.c. once weekly for 14 d) prevents Glucocorticoid-induced muscle wasting in mice^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1356922-05-8

Liquid

Colorless to light yellow

[Bimagrumab]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Heymsfield SB, et, al. Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity: A Phase 2 Randomized Clinical Trial. JAMA Netw Open. 2021 Jan 4;4(1):e2033457.  [Content Brief]

  [2]. Lach-Trifilieff E, et, al. An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy. Mol Cell Biol. 2014 Feb;34(4):606-18.  [Content Brief]